Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

Table 7 Multivariate analysis including patients who received stereotactic radiotherapy with dose/fractionation data (n = 1739)

		Hazard Ratio	95% Confidence Interval	p-value
Sex	Male	1.00	Ref	0.001
Sex	Female	0.82	0.73–0.92	0.001
Age	18–59	1.00	Ref	0.01
	60–69	1.12	0.97–1.29
	70–79	1.27	1.09–1.48
	80+	1.35	1.04–1.76
Comorbidity	0	1.00	Ref	0.004
	1	1.02	0.89–1.18
	> 2	1.41	1.15–1.73
Histology	Adenocarcinoma	1.00	Ref	< 0.0001
Histology	Non-adenocarcinoma	1.29	1.14–1.45	< 0.0001
Race	White	1.00	Ref	0.52
Race	Non-white	1.05	0.90–1.23	0.52
Insurance	Uninsured	1.00	Ref	0.77
Insurance	Insured	0.95	0.69–1.32	0.77
Facility Type	Academic	1.00	Ref	0.17
Facility Type	Nonacademic	1.09	0.97–1.22	0.17
Systemic Therapy	Chemotherapy	1.00	Ref	0.51
Systemic Therapy	Immunotherapy	1.08	0.86–1.37	0.51
Biologically Effective Dose	≤60 Gy	1.00	Ref	< 0.0001
Biologically Effective Dose	> 60 Gy	0.79	0.70–0.90	< 0.0001

ISSN: 1748-717X